Involvement of the BK channels/G proteins processes in the synergistic effects between anticholinergic agents and beta2 -adrenoceptor agonists in airway smooth muscle Source: Annual Congress 2013 –Novel mechanisms for established drugs for asthma and COPD management Year: 2013
Slow dissociation kinetics of LAMAs contribute to the functional interactions with LABAs Source: International Congress 2016 – Airway pharmacology: drug targets and mode of action Year: 2016
Pharmacological characterization of the mechanism of action leading to synergism between glycopyrronium bromide and indacaterol fumarate Source: International Congress 2016 – Airway pharmacology: drug targets and mode of action Year: 2016
Pharmacological interaction between glycopyrronium bromide and indacaterol fumarate on the human airways tone Source: International Congress 2016 – Preclinical pharmacology: drug targets and mechanisms of action Year: 2016
Synergistic effects between glycopyrronium bromide and indacaterol on a muscarinic agonist-induced contraction in airway smooth muscle Source: Annual Congress 2012 - The best of pharmacology treatment for asthma and COPD Year: 2012
A comparison of beta2 -adrenoceptor desensitisation induced by olodaterol and formoterol in human lung mast cells and airway smooth muscle cells Source: Annual Congress 2013 –New drugs in respiratory medicine Year: 2013
Repeated-dose pharmacokinetics of once-daily TD-4208, a long-acting muscarinic receptor antagonist (LAMA), in subjects with COPD Source: International Congress 2014 – Bronchodilators for asthma and COPD Year: 2014
Beneficial effects of menthol are mediated via a TRPM8-independent mechanism Source: International Congress 2015 – Novel targets and strategies for the treatment of cough, asthma, rhinosinusitis and COPD Year: 2015
Interaction between aclidinium bromide and formoterol fumarate; effects on human bronchial smooth muscle Source: International Congress 2014 – Novel evidence relating to respiratory treatment development Year: 2014
Abediterol, a novel long-acting inhaled beta2 -agonist, has a fast association rate and long residence time at human beta2 receptors Source: International Congress 2014 – Novel approaches and evidence for drug development in respiratory diseases Year: 2014
Bronchodilator activity of the combination of salbutamol hemisuccinate and methatropium iodide compared with monotherapy in preclinical studies Source: International Congress 2015 – Novel treatments for cough, asthma, COPD and bronchiectasis Year: 2015
Impaired inhibitory action of corticosteroids on chemokine expression induced by TNFalpha in airway smooth muscle (ASM) cells from patients with severe asthma Source: Annual Congress 2013 –Airway smooth muscle and cell biology Year: 2013
Abediterol has higher beta2 -receptor affinity and in vitro bronchodilatory potency than other long-acting beta2 -agonists, with good selectivity Source: International Congress 2014 – Novel evidence relating to respiratory treatment development Year: 2014
Effects of the new ultra-long-acting β2-AR agonist indacaterol in chronic treatment alone or in combination with the β1-AR blocker metoprolol on cardiac remodelling Source: International Congress 2015 – Safety of and interactions between current treatments for asthma and COPD Year: 2015
Abediterol has higher bronchodilatory potency and reduced cardiac effects versus other long-acting beta2 -agonists in dogs Source: International Congress 2014 – Rationale behind respiratory drug development Year: 2014
The combination therapy with inhaled tiotropium bromide and indacaterol in COPD improves the peripheral airway function in static and dynamic status Source: International Congress 2014 – Asthma and COPD management Year: 2014
The effect of adenosine on VEGF release from airway smooth muscle from subjects with asthma Source: Annual Congress 2013 –Airway smooth muscle and cell biology Year: 2013
Abediterol has higher bronchodilatory potency than other long-acting beta2 -receptor agonists in a guinea pig model Source: International Congress 2014 – Novel evidence relating to respiratory treatment development Year: 2014
Dose-related efficacy of GSK573719, a new long-acting muscarinic receptor antagonist (LAMA) offering sustained 24-hour bronchodilation, in COPD Source: Annual Congress 2011 - Bronchodilators in asthma and COPD Year: 2011
The dual PDE3/PDE4 phosphodiesterase inhibitor RPL554 produces more complete bronchodilator responses than the beta2-agonist salbutamol and the anti-muscarinic agent ipratropium bromide, alone and in combination, in guinea-pig isolated trachea Source: International Congress 2015 – Novel treatments for cough, asthma, COPD and bronchiectasis Year: 2015